Special Session
Expanding CKD Therapeutics: FIND-CKD and Beyond
October 22, 2026 | 04:30 PM - 06:00 PM
Location: Four Seasons Ballroom 1, Convention Center
Session Description
Recently, the FIND-CKD trial demonstrated the efficacy of a nonsteroidal mineralocorticoid antagonist in slowing eGFR decline among adults with CKD who do not have diabetes. This session presents additional analyses from this trial and other related studies that seek to define the scope and impact of this emerging treatment option in CKD.
Note: Continuing education credits are not being offered for this session.
Learning Pathway(s)
- CKD Non-Dialysis
Moderators
Presentations
-
Introduction
-
FIND-CKD Overview
-
Finerenone in Patients with CKD by SGLT2i Treatment
-
Hyperkalemia in Finerenone-Treated Patients with CKD Without Diabetes
-
Finerenone in Asian Patients with CKD
-
Effects of Finerenone on Risk Biomarkers of CKD Progression
-
Finerenone in Patients with IgA Nephropathy
-
Finerenone in Patients with FSGS
-
Effects of Finerenone on Clinical Outcomes by CKD Severity: INFINITY
-
Audience Q&A